Scholarly Publications
Permanent URI for this communityhttps://dl.bhu.ac.in/bhuir/handle/123456789/16335
This community showcases the academic contributions of faculty and researchers at Banaras Hindu University (BHU) and provides a year-wise compilation of publications across disciplines. Institutional Repository BHU
Browse
13 results
Search Results
Now showing 1 - 10 of 13
PublicationReview Ayush Kwath: A Major Contribution of Ayurveda in Preventing COVID-19 Infection(Bentham Science Publishers, 2024) Priya Katoch; Kirti Raina; Rohit Sharma; Ashun ChaudharyBackground: Ayush Kwath is an Ayurvedic polyherbal formulation (PHF) of dry Tulsi leaves, Cinnamon bark, Sunthi rhizome, and black pepper fruit. Methods: This PHF contain phytochemicals that help in boosting immunity; hence, it is suggested as a preventive measure against the coronavirus. Ayurveda is an ancient Indian medicine system that offers treatment for various diseases with the help of herbal, animal, or mineral-based formulations. Currently, the entire globe is facing the challenge of combating the COVID-19 pandemic. COVID-19 (Coronavirus disease 19) is a highly infectious disease caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus-2) that belongs to a large family of coronaviruses. Results: Most people who are affected by this virus experience mild to moderate symptoms of pneumonia, but older people or those with weakened immune systems, for example, those suffering from cancer, diabetes, cardiovascular disease, or chronic respiratory diseases, are more likely to develop serious respiratory illnesses. As there is no registered medicine against COVID-19, strengthening the immune system is an effective way to tackle this disease. Conclusion: Ayush Kwath, a natural immunity booster, has been approved by the Ministry of AYUSH as a prophylactic measure to fight against novel coronavirus infection. © 2024 Bentham Science Publishers.PublicationReview An Insight into COVID-19 and Traditional Herbs: Bangladesh Perspective(Bentham Science Publishers, 2023) Md. Mominur Rahman; Sheikh Shohag; Md. Rezaul Islam; Shomaya Akhter; Sadia Afsana Mim; Rohit Sharma; Abdur RaufSARS-CoV-2 was first discovered in Wuhan in late 2019 and has since spread over the world, resulting in the present epidemic. Because targeted therapeutics are unavailable, scientists have the opportunity to discover new drugs or vaccines to counter COVID-19, and therefore a number of synthetic bioactive compounds are now being tested in clinical studies. Due to its broad therapeutic spectrum and low adverse effects, medicinal herbs have been used as traditional healing medication in those countries for ages. Due to a lack of synthetic bioactive antiviral medications, pharmaceutical and alternative therapies have been developed using a variety of herbal compositions. Due to the wide-spread availability of herbal and dietary products worldwide, people frequently use them. Notably, the majority of Bangladeshi people continue to use a variety of natural plants and herbs to treat various types of diseases. This review article discusses how previous research has shown that some herbs in Bangladesh have immunomodulatory and antiviral effects and how their active ingredients have been gathered. Even though FDA-approved medications and vaccines are available for the treatment of COVID-19, the purpose is to encourage the use of herbal medicine as immunomodulators and vaccine adjuvants for the treatment of COVID-19 prevention. © 2023 Bentham Science Publishers.PublicationReview PDE5 inhibitors: Breaking new grounds in the treatment of COVID-19(Walter de Gruyter GmbH, 2023) Ryan Varghese; Gargi Digholkar; Jainam Karsiya; Sahil Salvi; Jeenam Shah; Dileep Kumar; Rohit SharmaDespite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment. Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system. Repurposing and developing phosphodiesterase 5 (PDE5) inhibitors could extrapolate their utility to combat the SARS-CoV-2 infection, and potentially aid in the management of the symptoms associated with its newer variants such as BF.7, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16. Administration of PDE5 inhibitors via the oral and intravenous route demonstrates other potential off-label benefits, including anti-apoptotic, anti-inflammatory, antioxidant, and immunomodulatory effects, by intercepting several pathways. These effects can not only be of clinical importance in mild-to-moderate, but also moderate-to-severe SARS-CoV-2 infections. This article explores the various mechanisms by which PDE5 inhibitors alleviates the symptoms associated with COVID-19 as well as well as highlights recent studies and findings. These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events. © 2023 Roman Suligowski et al., published by Sciendo 2023.PublicationLetter Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?(Springer, 2023) Ryan Varghese; Dileep Kumar; Rohit Sharma[No abstract available]PublicationArticle Smartphone-based diagnostics for biosensing infectious human pathogens(Elsevier Ltd, 2023) Aditya Amrut Pawar; Sanchita Bipin Patwardhan; Sagar Barage; Rajesh Raut; Jaya Lakkakula; Arpita Roy; Rohit Sharma; Jigisha AnandThe widespread usage of smartphones has made accessing vast troves of data easier for everyone. Smartphones are powerful, handy, and easy to operate, making them a valuable tool for improving public health through diagnostics. When combined with other devices and sensors, smartphones have shown potential for detecting, visualizing, collecting, and transferring data, enabling rapid disease diagnosis. In resource-limited settings, the user-friendly operating system of smartphones allows them to function as a point-of-care platform for healthcare and disease diagnosis. Herein, we critically reviewed the smartphone-based biosensors for the diagnosis and detection of diseases caused by infectious human pathogens, such as deadly viruses, bacteria, and fungi. These biosensors use several analytical sensing methods, including microscopic imaging, instrumental interface, colorimetric, fluorescence, and electrochemical biosensors. We have discussed the diverse diagnosis strategies and analytical performances of smartphone-based detection systems in identifying infectious human pathogens, along with future perspectives. © 2023 Elsevier LtdPublicationReview Reviewing methods of deep learning for diagnosing COVID-19, its variants and synergistic medicine combinations(Elsevier Ltd, 2023) Qandeel Rafique; Ali Rehman; Muhammad Sher Afghan; Hafiz Muhamad Ahmad; Imran Zafar; Kompal Fayyaz; Quratul Ain; Rehab A. Rayan; Khadija Mohammed Al-Aidarous; Summya Rashid; Gohar Mushtaq; Rohit SharmaThe COVID-19 pandemic has necessitated the development of reliable diagnostic methods for accurately detecting the novel coronavirus and its variants. Deep learning (DL) techniques have shown promising potential as screening tools for COVID-19 detection. In this study, we explore the realistic development of DL-driven COVID-19 detection methods and focus on the fully automatic framework using available resources, which can effectively investigate various coronavirus variants through modalities. We conducted an exploration and comparison of several diagnostic techniques that are widely used and globally validated for the detection of COVID-19. Furthermore, we explore review-based studies that provide detailed information on synergistic medicine combinations for the treatment of COVID-19. We recommend DL methods that effectively reduce time, cost, and complexity, providing valuable guidance for utilizing available synergistic combinations in clinical and research settings. This study also highlights the implication of innovative diagnostic technical and instrumental strategies, exploring public datasets, and investigating synergistic medicines using optimised DL rules. By summarizing these findings, we aim to assist future researchers in their endeavours by providing a comprehensive overview of the implication of DL techniques in COVID-19 detection and treatment. Integrating DL methods with various diagnostic approaches holds great promise in improving the accuracy and efficiency of COVID-19 diagnostics, thus contributing to effective control and management of the ongoing pandemic. © 2023 Elsevier LtdPublicationReview PDE5 inhibitors: breaking new grounds in the treatment of COVID-19(Walter de Gruyter GmbH, 2023) Ryan Varghese; Gargi Digholkar; Jainam Karsiya; Sahil Salvi; Jeenam Shah; Dileep Kumar; Rohit SharmaIntroduction: Despite the ever-increasing occurrences of the coronavirus disease (COVID-19) cases around the world, very few medications have been validated in the clinical trials to combat COVID-19. Although several vaccines have been developed in the past quarter, the time elapsed between deployment and administration remains a major impediment. Content: Repurposing of pre-approved drugs, such as phosphodiesterase 5 (PDE5) inhibitors, could be a game-changer while lessening the burden on the current healthcare system. Repurposing and developing phosphodiesterase 5 (PDE5) inhibitors could extrapolate their utility to combat the SARS-CoV-2 infection, and potentially aid in the management of the symptoms associated with its newer variants such as BF.7, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16. Summary: Administration of PDE5 inhibitors via the oral and intravenous route demonstrates other potential off-label benefits, including anti-apoptotic, anti-inflammatory, antioxidant, and immunomodulatory effects, by intercepting several pathways. These effects can not only be of clinical importance in mild-to-moderate, but also moderate-to-severe SARS-CoV-2 infections. This article explores the various mechanisms by which PDE5 inhibitors alleviates the symptoms associated with COVID-19 as well as well as highlights recent studies and findings. Outlook: These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events. © 2023 Walter de Gruyter GmbH, Berlin/Boston.PublicationReview Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant(John Wiley and Sons Inc, 2022) Vineet Sharma; Himanshu Rai; Dev N. S. Gautam; Pradeep K. Prajapati; Rohit SharmaCOVID's Omicron variant has sparked a slew of concerns across the globe. This review aims to provide a brief overview of what we know about the Omicron variant right now. The new variant has been discovered in 149 countries across all six World Health Organization (WHO) regions since its discovery in South Africa on November 24, 2021 and became the dominant variant in the country in less than 3 weeks. The WHO has warned that the B.1.1.529 variant is spreading at an unprecedented rate, and has urged countries to prepare for the worst. Over the course of this time, researchers from Africa and around the world have uncovered a wealth of information about the virus's epidemiology and biological properties. Case numbers are increasing exponentially in hard-hit areas such as South Africa, United Kingdom, and USA (overtaking the delta variant), implying that the variant is highly transmissible. Initial research has provided some insights into the efficacy of vaccines against the Omicron variant and whether it produces major illness, however, much remains unknown, and additional work is needed to investigate what the initial reports represent in real-world situations. © 2022 Wiley Periodicals LLCPublicationReview Mucormycosis in the COVID-19 Environment: A Multifaceted Complication(Frontiers Media S.A., 2022) Rohit Sharma; Praveen Kumar; Abdur Rauf; Ashun Chaudhary; Pradeep Kumar Prajapati; Talha Bin Emran; Clara Mariana Gonçalves Lima; Carlos Adam Conte-JuniorThe second wave of coronavirus disease 2019 (COVID-19) caused severe infections with high mortality. An increase in the cases of COVID-19-associated mucormycosis (CAM) was reported predominantly in India. Commonly present in immunocompromised individuals, mucormycosis is often a life-threatening condition. Confounding factors and molecular mechanisms associated with CAM are still not well understood, and there is a need for careful research in this direction. In this review, a brief account of the diagnosis, management, and advancement in drug discovery for mucormycosis has been provided. Here, we summarize major factors that dictate the occurrence of mucormycosis in COVID-19 patients through the analysis of published literature and case reports. Major predisposing factors to mucormycosis appear to be uncontrolled diabetes, steroid therapy, and certain cancers. At the molecular level, increased levels of iron in COVID-19 might contribute to mucormycosis. We have also discussed the potential role and regulation of iron metabolism in COVID-19 patients in establishing fungal growth. Other factors including diabetes prevalence and fungal spore burden in India as contributing factors have also been discussed. Copyright © 2022 Sharma, Kumar, Rauf, Chaudhary, Prajapati, Emran, Gonçalves Lima and Conte-Junior.PublicationReview Post-COVID-19 Trends in Indian Dairy Industry: Current Challenges, Recoveries and Future Strategies(Indian Veterinary Assocaition, 2022) Ankur Aggarwal; Tarun Verma; Dinesh Chandra Rai; Rohit SharmaThe COVID-19 outbreak and the subsequent lockdown have had a negative impact on agriculture and other allied activity i.e. food, livestock, dairy etc. The most important and essential aspect of a unsustainable turn of events due to COVID-19 is dairy sector. When it comes to supplying products to clients, dairy suppliers are facing a difficult situation. These disruptions have a sudden impact on the dairy supply chain system and the process can collapse if necessary and immediate actions are not taken. The pandemic and its associated lockdown have not only made it difficult for a large number of poor and marginal dairy farmers but have also had an impact on the livestock feed industry, dairy industry, and related supply value chains of the dairy sector. This review article features different elements of the effects, specifically decreased popularity of various products, wastage of products, supply market chains, work absenteeism due to shortage of labor, and recovery strategy taken by the authorities to recover livestock and dairy sector. This review article provides a comprehensive view of the overall situation, a methodical report gathering critical data across the country and the impact on every sub-area of the dairy sector and associated value supply chains. © 2022 Indian Veterinary Assocaition. All rights reserved.